Stevanato Group reported FY 2025 revenue of EUR 1.186 billion, up 7%, with gross profit margin of 29.0% and adjusted EBITDA margin of 25.1%. FY 2025 diluted EPS was EUR 0.51, up 19%, and adjusted diluted EPS was EUR 0.54, up 13%. High-value solutions represented 46% of FY revenue. Cash and cash equivalents were EUR 130.6 million at December 31, 2025, with net debt of EUR 337.7 million; FY 2025 free cash flow was EUR 18.4 million. For Q4 2025, revenue rose 5% to EUR 346.5 million, with high-value solutions revenue of EUR 171.4 million, up 31%, representing 49% of total revenue. Q4 gross profit margin was 30.9% and adjusted EBITDA margin was 28.2%; diluted EPS was EUR 0.17 and adjusted diluted EPS was EUR 0.18. In segment results for Q4, Biopharmaceutical and Diagnostic Solutions revenue increased 10% to EUR 307.1 million, while Engineering revenue decreased 23% to EUR 39.4 million. Management said biologics remained a key tailwind and that GLP-1 products represented approximately 19% to 20% of total company revenue in 2025, citing its global footprint and product quality as factors supporting GLP-1 market share gains. Stevanato Group also issued FY 2026 guidance for revenue of EUR 1.26 billion to EUR 1.29 billion, adjusted EBITDA of EUR 331.8 million to EUR 346.9 million, and adjusted diluted EPS of EUR 0.59 to EUR 0.63.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260304625622) on March 04, 2026, and is solely responsible for the information contained therein.